查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1635875

2025-2033年婴儿痉挛治疗市场依治疗类别、药物类型（氨己烯酸、促肾上腺皮质激素等）、剂量、给药途径、配销通路、最终用户和地区

Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others ), Dosage, Route of Administration, Distribution Channel, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 128 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球婴儿IMARC Group症治疗市场规模达38亿美元。婴儿癫痫发作的盛行率不断上升、大众健康意识的提高导致早期诊断、产品批准数量的增加以及强大的管道药物的存在是推动市场的一些关键因素。

婴儿痉挛疗法是指用于治疗幼儿癫痫发作或癫痫症候群的治疗程序，幼儿通常年龄在四个月到一岁之间。痉挛发作的特征是身体突然僵硬，手臂、腿和头部向前弯曲，背部拱起，以及短暂而微妙的癫痫发作。婴儿痉挛症可由脑肿瘤、出生损伤、脑部感染和基因改变引起。针对婴儿垃圾邮件有多种治疗选择，包括类固醇、促肾上腺皮质激素注射凝胶和糖皮质激素的荷尔蒙疗法以及抗癫痫药物。如果在痉挛发生后三週内实施婴儿痉挛症治疗，则更有可能提供持续的效果，并且可以透过单一疗法或合併疗法进行治疗。婴儿痉挛症可透过身体检查、神经系统检查、脑部 MRI 以及血液和尿液检查来诊断。

婴儿痉挛症治疗市场趋势：

新生儿中婴儿痉挛症盛行率的增加是推动市场成长的重要因素。这可以归因于全球出生率的大幅上升。与此一致的是，越来越多的产品批准和强大的管道药物的存在正在对市场产生积极影响。婴儿痉挛症治疗的持续技术进步，例如引入用于检测癫痫发作并提醒护理人员的癫痫警报装置，正在为市场提供动力。此外，人们对早期诊断和治疗的广泛认识正在提高婴儿痉挛症药物的渗透率，从而推动市场成长。然而，各种因素，例如治疗成功率较低、治疗成本较高、药物审批的严格规定以及未确诊患者数量的增加，正在阻碍婴儿痉挛症治疗市场的成长。相反，一些国家的政府和私人组织为提高人们对医疗状况的认识而采取的有利倡议和计划正在创造积极的市场前景。主要市场参与者所进行的广泛研发（R＆D）活动进一步推动了市场的发展，这些活动专注于开发成功率更高的创新药物。影响市场的其他一些因素包括不断扩大的医疗保健支出、不断增加的合作、伙伴关係和併购 (M&A)、快速城市化以及可支配收入水平的提高。

本报告回答的关键问题

  • 全球婴儿痉挛症治疗市场有多大？ 2025-2033年全球婴儿痉挛症治疗市场的预期成长率是多少？
  • 推动全球婴儿痉挛症治疗市场的关键因素是什么？
  • COVID-19 对全球婴儿痉挛症治疗市场有何影响？
  • 根据治疗类别，全球婴儿痉挛症治疗市场的细分如何？
  • 根据药物类型，全球婴儿痉挛症治疗市场的细分如何？
  • 根据剂量，全球婴儿痉挛症治疗市场的细分如何？
  • 根据给药途径，全球婴儿痉挛症治疗市场的细分如何？
  • 基于配销通路的全球婴儿痉挛症治疗市场的细分情况如何？
  • 基于最终用户的全球婴儿痉挛症治疗市场的细分情况如何？
  • 全球婴儿痉挛症治疗市场的关键地区有哪些？
  • 谁是全球婴儿痉挛症治疗市场的主要参与者/公司？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球婴儿痉挛症治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依治疗类别

  • 抗惊厥药
    • 市场趋势
    • 市场预测
  • 皮质类固醇
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依药物类型

  • 氨己烯酸
    • 市场趋势
    • 市场预测
  • 促肾上腺皮质激素
    • 市场趋势
    • 市场预测
  • 其他（三期）
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按剂量

  • 坚硬的
    • 市场趋势
    • 市场预测
  • 液体
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：依管理途径

  • 口服
    • 市场趋势
    • 市场预测
  • 注射用
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按配销通路

  • 医院药房
    • 市场趋势
    • 市场预测
  • 零售药房
    • 市场趋势
    • 市场预测
  • 网路药房
    • 市场趋势
    • 市场预测

第 11 章：市场区隔：依最终用户

  • 医院
    • 市场趋势
    • 市场预测
  • 诊所
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 12 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 13 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 14 章：价值链分析

第 15 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 16 章：价格分析

第17章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • H. Lundbeck A/S
    • Mallinckrodt plc
    • ORPHELIA Pharma
    • Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.)
Product Code: SR112025A6789

The global infantile spasms therapeutics market size reached USD 3.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.2 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033. The rising prevalence of seizures in infants, increasing health consciousness among the masses resulting in early diagnosis, and the growing number of product approvals and presence of strong pipelines drugs represent some of the key factors driving the market.

Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures. Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes. There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.

Infantile Spasms Therapeutics Market Trends:

The increasing prevalence of infantile spasms among newborn babies is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the birth rates across the globe. In line with this, the growing number of product approvals and presence of strong pipelines drugs are impacting the market positively. Continual technological advancements in the treatment of infantile spasms, such as the introduction of seizure alert device for detecting seizures and alerting the caregivers, are providing an impetus to the market. Also, the widespread awareness regarding early diagnosis and treatment is enhancing the penetration rate of infantile spasm drugs, thereby fueling the market growth. However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook. The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.

Key Market Segmentation:

Therapeutic Class Insights:

  • Anticonvulsants
  • Corticosteroids
  • Others

Drug Type Insights:

  • Vigabatrin
  • Adrenocorticotropic Hormone
  • Others (Phase III)

Dosage Insights:

  • Solid
  • Liquid

Route of Administration Insights:

  • Oral
  • Parenteral
  • Others

Distribution Channel Insights:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

End User Insights:

  • Hospitals
  • Clinics
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for infantile spasms therapeutics. Some of the factors driving the North America infantile spasms therapeutics market include the presence of several key players, inflating disposable income levels, and the widespread awareness regarding early disease diagnosis and prevention.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global infantile spasms therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global infantile spasms therapeutics market?
  • 2. What is the expected growth rate of the global infantile spasms therapeutics market during 2025-2033?
  • 3. What are the key factors driving the global infantile spasms therapeutics market?
  • 4. What has been the impact of COVID-19 on the global infantile spasms therapeutics market?
  • 5. What is the breakup of the global infantile spasms therapeutics market based on the therapeutic class?
  • 6. What is the breakup of the global infantile spasms therapeutics market based on the drug type?
  • 7. What is the breakup of the global infantile spasms therapeutics market based on the dosage?
  • 8. What is the breakup of the global infantile spasms therapeutics market based on route of administration?
  • 9. What is the breakup of the global infantile spasms therapeutics market based on the distribution channel?
  • 10. What is the breakup of the global infantile spasms therapeutics market based on the end user?
  • 11. What are the key regions in the global infantile spasms therapeutics market?
  • 12. Who are the key players/companies in the global infantile spasms therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Infantile Spasms Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapeutic Class

  • 6.1 Anticonvulsants
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Corticosteroids
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Vigabatrin
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Adrenocorticotropic Hormone
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others (Phase III)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Dosage

  • 8.1 Solid
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Liquid
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacy
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacy
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacy
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by End User

  • 11.1 Hospitals
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Clinics
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Others
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 Drivers, Restraints, and Opportunities

  • 13.1 Overview
  • 13.2 Drivers
  • 13.3 Restraints
  • 13.4 Opportunities

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 H. Lundbeck A/S
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 Mallinckrodt plc
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
      • 17.3.2.3 Financials
    • 17.3.3 ORPHELIA Pharma
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
    • 17.3.4 Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.)
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Infantile Spasms Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Infantile Spasms Therapeutics Market: Breakup by Therapeutic Class (in %), 2024
  • Figure 5: Global: Infantile Spasms Therapeutics Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Infantile Spasms Therapeutics Market: Breakup by Dosage (in %), 2024
  • Figure 7: Global: Infantile Spasms Therapeutics Market: Breakup by Route of Administration (in %), 2024
  • Figure 8: Global: Infantile Spasms Therapeutics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 9: Global: Infantile Spasms Therapeutics Market: Breakup by End User (in %), 2024
  • Figure 10: Global: Infantile Spasms Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 11: Global: Infantile Spasms Therapeutics (Anticonvulsants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Infantile Spasms Therapeutics (Anticonvulsants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Infantile Spasms Therapeutics (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Infantile Spasms Therapeutics (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Infantile Spasms Therapeutics (Other Therapeutic Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Infantile Spasms Therapeutics (Other Therapeutic Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Infantile Spasms Therapeutics (Vigabatrin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Infantile Spasms Therapeutics (Vigabatrin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Infantile Spasms Therapeutics (Adrenocorticotropic Hormone) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Infantile Spasms Therapeutics (Adrenocorticotropic Hormone) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Infantile Spasms Therapeutics (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Infantile Spasms Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Infantile Spasms Therapeutics (Solid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Infantile Spasms Therapeutics (Solid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Infantile Spasms Therapeutics (Liquid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Infantile Spasms Therapeutics (Liquid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Infantile Spasms Therapeutics (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Infantile Spasms Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Infantile Spasms Therapeutics (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Infantile Spasms Therapeutics (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Infantile Spasms Therapeutics (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Infantile Spasms Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Infantile Spasms Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Infantile Spasms Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Infantile Spasms Therapeutics (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Infantile Spasms Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Infantile Spasms Therapeutics (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Infantile Spasms Therapeutics (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Infantile Spasms Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Infantile Spasms Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Infantile Spasms Therapeutics (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Infantile Spasms Therapeutics (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Infantile Spasms Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Infantile Spasms Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: North America: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: North America: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: United States: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: United States: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Canada: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Canada: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Asia-Pacific: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Asia-Pacific: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: China: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: China: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Japan: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Japan: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: India: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: India: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: South Korea: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: South Korea: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Australia: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Australia: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Indonesia: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Indonesia: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Europe: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Europe: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Germany: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Germany: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: France: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: France: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: United Kingdom: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: United Kingdom: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Italy: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Italy: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Spain: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Spain: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Russia: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Russia: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Others: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Others: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Latin America: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Latin America: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Brazil: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Brazil: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Mexico: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Mexico: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Others: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Others: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Middle East and Africa: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Middle East and Africa: Infantile Spasms Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 93: Middle East and Africa: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Global: Infantile Spasms Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 95: Global: Infantile Spasms Therapeutics Industry: Value Chain Analysis
  • Figure 96: Global: Infantile Spasms Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Infantile Spasms Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Therapeutic Class (in Million USD), 2025-2033
  • Table 3: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Dosage (in Million USD), 2025-2033
  • Table 5: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 7: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 8: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 9: Global: Infantile Spasms Therapeutics Market: Competitive Structure
  • Table 10: Global: Infantile Spasms Therapeutics Market: Key Players